Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK
$599.00
Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK
$599.00
An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.
SKU: N/A
Author: Datamonitor Healthcare
Publisher: Biomedtracker
Published: 19 November 2018
Number of pages:14
Formats:PDF
Report code:TL #10065
Highlights
Description
Highlights
“Vaccine effectiveness is the biggest unmet need, and maybe another biggest unmet need is to cover well the AH3 and 2, we are not covering that well and that is very costly among the elderly.”
“I think the biggest unmet need is that the number of people who are actually vaccinated, if you combine all age groups it is still in the 50% range, and there is a lot of room for improvement.”
Drug Coverage
Fluad
Fluzone High dose
FluMist Quadrivalent
Flublok
Flucelvax
Universal flu vaccines
Overview
An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.